Zhencheng Lin
林祯成
Zhencheng Lin (林祯成) is a partner at Dalton Venture (道彤投资), a healthcare-focused investment firm, where he has progressed from managing director to partner between 2022 and 2024 . He specializes in medical technology and healthcare innovation, with particular focus on cardiovascular disease, brain-computer interfaces, and neuromodulation . At the 2026 World AI Conference, he discussed investment logic around brain-computer interfaces and AI for Science . He led Dalton's investment in New Cloud Medical (新云医疗), a chronic pain device company, in its 2025 Series B+ round, and has been vocal about the growing demand for pain management solutions amid China's aging population .
AI-generated — may contain errors, please verify.
Coverage
How to Invest in Brain-Computer Interfaces? Dalton Venture's Lin Zhengcheng Breaks Down the Underlying Investment Logic at WAIC
**During the 2026 World Artificial Intelligence Conference (WAIC), Lin Zhengcheng, Partner at Dalton Venture, was invited to join Observer Network's *Zhi Guan WAIC 2026* livestream for nearly an hour of in-depth discussion on frontier technologies including brain-computer interfaces and AI for Science.** Rather than chasing industry buzzwords, Dalton Venture hoped to use this opportunity to present a long-developed research framework: as artificial intelligence continues to push toward the frontiers of science, the life sciences
Rushi Robotics Closes 100 Million Yuan Pre-A Round to Build Embodied Intelligence Platform for Real-World Elder Care Scenarios | Tongcheng Family
Recently, **Dalton Venture portfolio company Shanghai Rushen Robotics Technology Co., Ltd.** (hereinafter referred to as "Rushen Robotics") **announced the completion of a 100-million-yuan Pre-A funding round**, with investment from Qingsong Capital, leading listed computing power company Range Intelligent Computing Technology, and Pinghu Zexin. This round of financing will strongly support Rushen Robotics' continuous operation in real elderly care scenarios, data generation, and model iteration. This follows Dalton Venture's sole investment in Rushen Robotics in September 2025
Mycowave Medical Completes Tens of Millions of RMB Angel Round, with Dalton Venture as Sole Investor, Expanding Non-Invasive Neuromodulation for Home and Diversified Scenarios | Dalton News
Recently, emerging neuromodulation company **MicroVention Medical Technology (Shanghai) Co., Ltd.** (abbreviated as "MicroVention Medical") announced the completion of a tens-of-millions-of-yuan angel funding round. The round was **exclusively invested by Dalton Venture**, marking the company's first external financing since its establishment in 2024.
Xinyun Medical Closes Tens of Millions of RMB in Series B+ Funding Led by Dalton Venture, Building Innovative Devices and Neuromodulation Solutions for Chronic Pain | Dalton News
AI is emerging as a new engine for breaking through in pain treatment
Aiyisheng Completes Angel Round with DaoTong as Sole Investor, Accelerating Clinical Trials for Small-Caliber Artificial Blood Vessels | DaoTong News
Recently, **Aison (Guangzhou) Biotech Co., Ltd.** (hereinafter referred to as Aison Medical) **announced the completion of its angel round, led exclusively by Dalton Venture.** The proceeds will be primarily used to advance the clinical development of small-diameter artificial blood vessels and to expand applications of its core technology.
How Does Dalton Venture Precisely Capture Investment Growth Opportunities by Focusing on Cardiovascular Disease Diagnosis, Treatment, and Management? | Dalton Insights
For decades, cardiovascular disease has been considered the "leading killer" threatening global human health and longevity, with mortality rates reaching 5% among patients over 65. As population aging accelerates and lifestyles shift, the prevalence of chronic heart conditions is rising markedly — spurring waves of innovation across cardiovascular device segments to address persistent treatment pain points and improve diagnostic and therapeutic efficiency and safety.
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Rooted in Reality, Driven by Innovation, Moving Forward Without Pause | Dalton Venture's 2024 Annual Partners Meeting Successfully Concludes
Pressing forward into the real, advancing toward the new — the resolve to push ahead undimmed.
Dalton Venture's Lin Zhencheng: Technology Commercialization Gains Momentum, Capital Should Do More to Help Projects Cross the Commercialization Chasm | Dalton Insights
Dalton Venture's Lin Zhencheng was invited to participate in the Future Healthcare 100 · Trend Summit to discuss the next disruptive innovation track in life sciences.
Spring Tide Surges, A Thousand Sails Compete — Dalton Venture Annual CEO Summit | Tong Learning Society
Gather friends, gather energy, gather spirit
Survival of the Fittest | Dalton Venture 2022 Annual Partners Meeting (Part 2)
Deep post-investment management has always been one of Dalton Venture's distinguishing strengths. How does that post-investment support ultimately translate into portfolio company growth?
